Abstract
Purpose
Currently, there is a lack of research comparing tadalafil treatment protocols recommended during low-intensity shock wave therapy (LI-SWT) for patients with erectile dysfunction (ED) who are unresponsive to phosphodiesterase type 5 inhibitors (PDE5i). The objective of this study is to compare the efficacy of only LI-SWT versus LI-SWT plus 5 mg tadalafil daily versus LI-SWT plus 20 mg tadalafil alternate-day in PDE5i -resistant ED.
Materıals and methods
In this study, a cohort of 105 patients with PDE5i-resistant ED was recruited and divided into three groups labeled as A (only LI-SWT), B (LI-SWT plus 5 mg tadalafil daily), and C (LI-SWT plus 20 mg tadalafil alternate-day), comprising 27, 42, and 36 patients, respectively. The patients' International Index of Erectile Function-5 (IIEF-5) scores and the Erection Hardness Score (EHS) were evaluated at the baseline, three months and six months following the treatment.
Results
After three months post-treatment, the IIEF-5 scores in group A, B, and C increased by 4.1 ± 0.6, 7.3 ± 0.6, and 8.2 ± 0.6, respectively. These improvements were maintained at six months with IIEF-5 scores increasing by 3.7 ± 0.6, 7.3 ± 0.6, and 8.5 ± 0.7 in groups A, B, and C, respectively. At 3 and 6 months post-treatment, groups B and C showed significant improvement in IIEF-5 scores and EHS values compared to group A (p < 0.001). The rate of patients with EHS ≥ 3 and IIEF-5 ≥ 17 was significantly higher in groups B and C compared to group A, while there was no significantly different between groups B and C.
Conclusıon
In patients with PDE5i-resistant ED, PDE5i combined with LI-SWT is superior to LI-SWT monotherapy. The statistical analysis failed to demonstrate any difference between two distinct tadalafil regimens when administered with LI-SWT treatment.
Similar content being viewed by others
Data availability
The datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.
References
Gong B, Ma M, Xie W et al (2017) Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol 49:1731–1740
Salonia ABC, Capogrosso P, Carvalho J, Corona G, Hatzichristodoulou G, Jones TH, Kadioglu A, Martinez-Salamanca JI, Minhas S, Serefoglu EC, Verze P (2023) EAU guidelines on sexual and reproductive health [Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Sexual-and-Reproductive-Health-2023.pdf.
McCabe MP, Matic H (2008) Erectile dysfunction and relationships: views of men with erectile dysfunction and their partners. Sex Relatsh Ther 23(1):51–60
Althof SE, O’Leary MP, Cappelleri JC et al (2006) Impact of erectile dysfunction on confidence, self-esteem and relationship satisfaction after 9 months of sildenafil citrate treatment. J Urol 176(5):2132–2137
Lee D, Nazroo J, Pendleton N (2015) Erectile dysfunction and phosphodiesterase type 5 inhibitor use: associations with sexual activities, function and satisfaction in a population sample of older men. Int J Impot Res 27(4):146–151
Vita R, Benvenga S, Giammusso B et al (2019) Determinants of early response to low-intensity extracorporeal shockwaves for the treatment of vasculogenic erectile dysfunction: an open-label, prospective study. J Clin Med 8(7):1017
Vinay J, Moreno D, Rajmil O et al (2021) Penile low intensity shock wave treatment for PDE5I refractory erectile dysfunction: a randomized double-blind sham-controlled clinical trial. World J Urol 39:2217–2222
Mykoniatis I, Pyrgidis N, Sokolakis I et al (2021) Assessment of combination therapies vs monotherapy for erectile dysfunction: a systematic review and meta-analysis. JAMA Netw Open 4(2):e2036337
Jeon SH, Shrestha KR, Kim RY et al (2016) Combination therapy using human adipose-derived stem cells on the cavernous nerve and low-energy shockwaves on the corpus cavernosum in a rat model of post-prostatectomy erectile dysfunction. Urology 88(226):e1–e9
Brock GB, McMahon CG, Chen K et al (2002) Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 168(4):1332–1336
Brock G, Ni X, Oelke M et al (2016) Efficacy of continuous dosing of tadalafil once daily vs tadalafil on demand in clinical subgroups of men with erectile dysfunction: a descriptive comparison using the integrated tadalafil databases. J Sex Med 13(5):860–875
Mirone V, Costa P, Damber J-E et al (2005) An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Eur Urol 47(6):846–854
Nguyen Q, Van Do H (2022) Assessment of the results of treatment erectile dysfunction in diabetic patients by tadalafil 20mg once every there days. J Sex Med 19(5):S188
Grandez-Urbina JA, Rodríguez RP, Torres-Román JS et al (2020) Low-intensity extracorporeal shock wave treatment improves erectile function in non-responder PDEi5 patients: a systematic review. Rev Int de Androl 19(4):272–280
Zhu GQ, Jeon SH, Bae WJ et al (2018) Efficient promotion of autophagy and angiogenesis using mesenchymal stem cell therapy enhanced by the low-energy shock waves in the treatment of erectile dysfunction. Stem Cells Int 2018:14
Ruffo A, Stanojevic N, Romeo G et al (2020) PS-5-3 management of erectile dysfunction using a combination treatment of low-intensity shock waves (LISW) and platelet rich plasma (PRP) intracavernosal injections. J Sex Med 17(6):S133–S134
Kitrey ND, Gruenwald I, Appel B et al (2016) Penile low intensity shock wave treatment is able to shift PDE5i nonresponders to responders: a double-blind, sham controlled study. J Urol 195(5):1550–1555
Bechara A, Casabé A, De Bonis W et al (2016) Twelve-month efficacy and safety of low-intensity shockwave therapy for erectile dysfunction in patients who do not respond to phosphodiesterase type 5 inhibitors. Sex Med 4(4):e225–e232
Verze P, Capece M, Creta M et al (2020) Efficacy and safety of low-intensity shockwave therapy plus tadalafil 5 mg once daily in men with type 2 diabetes mellitus and erectile dysfunction: a matched-pair comparison study. Asian J Androl 22(4):379
Gruenwald I, Appel B, Vardi Y (2012) Low-intensity extracorporeal shock wave therapy—a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. J Sex Med 9(1):259–264
Vena W, Vaccalluzzo L, Morenghi E et al (2021) Low-intensity shockwave treatment (liswt) improves penile rigidity in eugonadal subjects with erectile dysfunction: a pilot study. Minerva Endocrinol 48(1):4–11
Funding
The authors declare that they have no relevant financial.
Author information
Authors and Affiliations
Contributions
MAI & FO performed the research, CA & ZT analyzed the data and wrote the paper, and OY designed the research study and wrote the paper. All authors approve the final version of the text.
Corresponding author
Ethics declarations
Conflict of interest
No conflict of interest was declared by the authors.
Ethical approval
The study was approved by the Ankara University Faculty of Medicine Ethics Committee (protocol number [i06-397–23]).
Informed consent
This is a retrospective analysis based on electronic medical record data. According to the requirements of ethics committee of Ankara University, informed consent can be exempted after anonymization of medical record data.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
İbis, M.A., Ozkaya, F., Tokatli, Z. et al. Efficacy of low-intensity shockwave therapy with different tadalafil regimens in patients with PDE5 inhibitor-resistant erectile dysfunction: a retrospective cohort study. Int Urol Nephrol 56, 407–413 (2024). https://doi.org/10.1007/s11255-023-03769-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-023-03769-w